Cisplatin: 158 Real Stories

158 stories match cisplatin. 156 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV NSCLC with brain and leptomeningeal metastases responding to radiotherapy, camrelizumab, GM-CSF, and chemotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Lung cancer markers supported adenocarcinoma. PD-L1 negative; no common lung driver found; TMB high; MSI not detected.

Metastatic Site: brain, leptomeningeal disease, left supraclavicular…

As of March 2025, leptomeningeal metastases had complete response, brain lesions had further regression, the lung lesion had decreased from 76 mm to 21 mm, and overall disease remained in partial response with 69 months of progression-free survival since radiotherapy.

PubMed Central
OutcomeResponding Well
Tina, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Tina's Patient Story

Patient Info: Tina Powell, Female | Stage IV

As of November 2025, Tina was living with Stage IV lung cancer after 27 chemotherapy rounds over 3 years and was receiving an antibody-drug conjugate in a clinical trial.

YouTube (AR search)
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage III Small Cell Lung CancerOvarian Cancer

Young Woman With Rare Small Cell Ovarian Cancer and Abdominal Recurrence

Patient Info: Anonymized, female, Under 40 | Stage III

Biomarkers: loss of SMARCA4 expression; retained SMARCB1 expression

The recurrent cancer continued to progress despite further chemotherapy, and she died at home 26 months after the initial diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Second primary Stage I lung adenocarcinoma treated with segmentectomy and adjuvant pembrolizumab

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: PD-L1 <1%; no common targetable lung cancer changes found in EGFR, ALK, KRAS, BRAF, MET, PIK3CA, RET, ROS1, or NTRK.

At 6-month oncologic follow-up, PET-CT showed complete metabolic response with no evidence of residual disease after segmentectomy and adjuvant pembrolizumab.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IVA lung adenocarcinoma: fatal hemoptysis from pulmonary artery pseudoaneurysm after chemoradiotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CEA 62 ng/mL; CA19-9 and neuron-specific enolase within normal limits; no molecular biomarkers reported

Metastatic Site: bone (11th thoracic vertebra)

The patient died from airway obstruction after massive hemoptysis caused by rupture of a pulmonary artery pseudoaneurysm that developed at the tumor-invaded pulmonary artery site after chemoradiotherapy.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA lung adenocarcinoma: complete metabolic remission after chemoradiotherapy, complicated by radiation esophagitis

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: No molecular biomarkers reported

The primary lung lesion achieved complete metabolic remission after concurrent chemoradiotherapy, and radiation esophagitis/stricture improved with conservative management until swallowing returned to a normal diet by 16 months.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA KRAS p.G12V lung adenocarcinoma: pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: KRAS p.G12V mutation; PD-L1 0% tumor-cell staining; <1% tumor-associated inflammatory-cell staining; no EGFR, ALK, or ROS1 driver mutation reported

Pathology after lobectomy showed a pathologic complete response, and surveillance imaging 12 months later showed no evidence of disease recurrence.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA lung adenocarcinoma complicated by severe atezolizumab-induced liver toxicity

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: PD-L1 49%; case text describes triple-negative status without expanding the specific markers

The patient was discharged clinically stable but with guarded prognosis after atezolizumab-induced vanishing bile duct syndrome, requiring prednisone, mycophenolate mofetil, ursodeoxycholic acid, prophylaxis, and close oncology/internal medicine follow-up.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

Triple-negative breast cancer history with later chest wall sarcomatoid carcinoma treated by embolization, ablation, and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Initial breast cancer was triple-negative. Later chest-wall lesion was weak ER-positive, PR/HER2-negative

By February 2025, the treated chest wall lesion had decreased to about 13 x 7 mm after embolization, radiofrequency ablation, and albumin-bound paclitaxel plus cisplatin, with no peripheral or distant metastatic foci seen.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Metastatic lung adenocarcinoma with brain and iliac bone response to chemoimmunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1-negative; no EGFR, ALK, ROS1, RET, KRAS, BRAF, MET, HER2, or NTRK alteration detected; TP53 mutation found.

Metastatic Site: left iliac bone, brain

Brain metastases achieved complete remission without cranial irradiation, and lung, bone, and brain lesions remained stable at last follow-up, with PFS of 35 months and OS exceeding 40 months.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV lung adenocarcinoma with Aspergillus-associated empyema: disease control after chemotherapy and antifungal therapy

Patient Info: Anonymized, Male | Stage IV

Biomarkers: Pathogenic NF1 mutation; CEA elevated in pleural fluid; Aspergillus fumigatus cultured from bronchoalveolar lavage fluid

Metastatic Site: pleural disease/effusion (M1a)

After 6 cycles of pemetrexed/cisplatin and 6 months of antifungal therapy for Aspergillus-associated empyema, 12-month follow-up showed disease stability without recurrence.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Metastatic lung adenocarcinoma with HER2 V659E/amplification responding to trastuzumab deruxtecan

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial lung testing showed no EGFR/ALK/ROS1 and PD-L1 TPS 3%. Later biopsy found HER2 V659E plus HER2 amplification.

Metastatic Site: liver, bone, brain

As of September 2024, metastatic lung adenocarcinoma had a sustained partial response to trastuzumab deruxtecan after HER2 V659E mutation and HER2 amplification were identified.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIA EGFR lung adenocarcinoma: no recurrence after early osimertinib stop

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: EGFR exon 19 deletion mutation; elevated KL-6 and SP-D during interstitial lung disease episode

During 9 months of follow-up after osimertinib was stopped, she had no recurrence of interstitial lung disease, pulmonary embolism, or non-small cell lung cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Extensive-stage small cell lung cancer with brain and adrenal progression after prolonged disease control

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Small-cell lung cancer markers included CD56, CgA and TTF-1; Ki-67 was 80%.

Metastatic Site: brain, right adrenal gland, left adrenal gland

After 31 months of stability on second-line anlotinib with palliative chemoradiotherapy, disease progressed in July 2024 with new brain lesions and adrenal progression; the patient declined additional systemic options and continued anlotinib.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic Neuroendocrine Breast Cancer With Severe Hormone Overproduction

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER-negative, PR focally positive, HER2-negative, PIK3CA mutation

Metastatic Site: liver, bone

Died after rapid deterioration and cardiac arrest during progressive metastatic disease.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Metastatic lung adenocarcinoma: complete remission on nivolumab complicated by immune-mediated diabetes

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Lung tumor: EGFR wild type, ALK rearrangement not detected. Immune-mediated diabetes: islet/GAD antibodies negative and C-peptide undetectable.

Metastatic Site: brain (cerebellum and occipital lobe); liver

As of March 2025, serial CT and MRI scans through October 2023 showed no evidence of oncologic disease after nivolumab, while immune-mediated diabetes was controlled with basal-bolus insulin.

PubMed Central
OutcomeCancer-Free / NED